Evidence map›Paper›PMID 40761670›Full record

ArticleDrug design, development and therapy2025

Leonurine Attenuates CCl

Pengru Wang, Junjie Bai, Mingxin Ye, Zhiwei Huang, Jiatong Chen, Lei Sun, Xiaolin Zhong, Yang Zheng, Tingting Ma, Wenguang Fu and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Pengru Wang *Metabolic Hepatobiliary and Pancreatic Diseases Key Laboratory of Luzhou City, Academician (Expert) Workstation of Sichuan Province, the Affiliated Hospital, Southwest Medical University, Luzhou, 646000, People's Republic of China.ORCID 0009-0008-5292-4594
Junjie Bai *Metabolic Hepatobiliary and Pancreatic Diseases Key Laboratory of Luzhou City, Academician (Expert) Workstation of Sichuan Province, the Affiliated Hospital, Southwest Medical University, Luzhou, 646000, People's Republic of China.
Mingxin YeDepartment of General Surgery (Hepatopancreatobiliary Surgery), the Affiliated Hospital, Southwest Medical University, Luzhou, 646000, People's Republic of China.
Zhiwei HuangMetabolic Hepatobiliary and Pancreatic Diseases Key Laboratory of Luzhou City, Academician (Expert) Workstation of Sichuan Province, the Affiliated Hospital, Southwest Medical University, Luzhou, 646000, People's Republic of China.ORCID 0000-0001-9672-8079
Jiatong ChenMetabolic Hepatobiliary and Pancreatic Diseases Key Laboratory of Luzhou City, Academician (Expert) Workstation of Sichuan Province, the Affiliated Hospital, Southwest Medical University, Luzhou, 646000, People's Republic of China.
Lei SunMetabolic Hepatobiliary and Pancreatic Diseases Key Laboratory of Luzhou City, Academician (Expert) Workstation of Sichuan Province, the Affiliated Hospital, Southwest Medical University, Luzhou, 646000, People's Republic of China.
Xiaolin ZhongDepartment of Gastroenterology, The Affiliated Hospital of Southwest Medical University, Luzhou, People's Republic of China.
Yang ZhengDrug Clinical Trial Institution, The Affiliated Hospital of Southwest Medical University, Luzhou, 646000, People's Republic of China.
Tingting MaClinical Medical Research Center, the Affiliated Hospital of Southwest Medical University, Luzhou, People's Republic of China.
Wenguang FuMetabolic Hepatobiliary and Pancreatic Diseases Key Laboratory of Luzhou City, Academician (Expert) Workstation of Sichuan Province, the Affiliated Hospital, Southwest Medical University, Luzhou, 646000, People's Republic of China.
Yichao DuMetabolic Hepatobiliary and Pancreatic Diseases Key Laboratory of Luzhou City, Academician (Expert) Workstation of Sichuan Province, the Affiliated Hospital, Southwest Medical University, Luzhou, 646000, People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Purpose: The repair response to persistent damage in the liver manifests as liver fibrosis. Leonurine (Leo), an herbal remedy from traditional Chinese medicine, exhibits multiple biological activities such as antioxidant and anti-inflammatory effects. Nevertheless, research exploring Leo's influence on liver fibrosis remains absent. This study aims to investigate the effect of Leo on liver fibrosis and clarify the mechanisms at play. Methods: We employed a mouse model of liver fibrosis induced by carbon tetrachloride (CCl Results: Mice administered CCl Conclusion: The findings indicate that Leo may exert a protective effect against liver fibrosis through the inhibition of the Hippo-YAP signaling pathway, underscoring its potential as a therapeutic agent for treating hepatic fibrosis.

Indexed as

Adaptor Proteins, Signal TransducingGallic AcidLiver CirrhosisProtein Serine-Threonine KinasesAnimalsApoptosisCarbon TetrachlorideCell Cycle ProteinsDisease Models, AnimalDose-Response Relationship, DrugHepatic Stellate CellsHippo Signaling PathwayHumansMaleMiceMice, Inbred C57BLAdaptor Proteins, Signal TransducingCarbon TetrachlorideCell Cycle ProteinsGallic AcidleonurineProtein Serine-Threonine KinasesYap1 protein, mouseYAP-Signaling Proteinsapoptosiscell cyclehepatic stellate cellsleonurineliver fibrosisyes-associated protein

Identifiers

PMID40761670
PMCPMC12320140

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.